These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31984667)

  • 1. Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation.
    Tanaka R; Umemura M; Narikawa M; Hikichi M; Osaw K; Fujita T; Yokoyama U; Ishigami T; Tamura K; Ishikawa Y
    ESC Heart Fail; 2020 Apr; 7(2):588-603. PubMed ID: 31984667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Doxorubicin directly induced fibrotic change of cardiac fibroblasts].
    Umemura M; Narikawa M; Tanaka R; Nemoto H; Nakakaji R; Nagasako A; Ishikawa Y
    Nihon Yakurigaku Zasshi; 2021; 156(3):146-151. PubMed ID: 33952842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.
    Bai Y; Chen Q; Sun YP; Wang X; Lv L; Zhang LP; Liu JS; Zhao S; Wang XL
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
    Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
    Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LongShengZhi capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress.
    Xu S; Wang Y; Yu M; Wang D; Liang Y; Chen Y; Liao C; Xie Z; Zhao B; Han J; Duan Y; Yang X
    Biomed Pharmacother; 2020 Mar; 123():109803. PubMed ID: 31877550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of miR-23a attenuates doxorubicin-induced mitochondria-dependent cardiomyocyte apoptosis by targeting the PGC-1α/Drp1 pathway.
    Du J; Hang P; Pan Y; Feng B; Zheng Y; Chen T; Zhao L; Du Z
    Toxicol Appl Pharmacol; 2019 Apr; 369():73-81. PubMed ID: 30831132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity.
    Zhu W; Reuter S; Field LJ
    Cardiovasc Res; 2019 Apr; 115(5):960-965. PubMed ID: 30423020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction.
    Tian XQ; Ni XW; Xu HL; Zheng L; ZhuGe DL; Chen B; Lu CT; Yuan JJ; Zhao YZ
    Int J Nanomedicine; 2017; 12():7103-7119. PubMed ID: 29026304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy.
    Lódi M; Priksz D; Fülöp GÁ; Bódi B; Gyöngyösi A; Nagy L; Kovács Á; Kertész AB; Kocsis J; Édes I; Csanádi Z; Czuriga I; Kisvárday Z; Juhász B; Lekli I; Bai P; Tóth A; Papp Z; Czuriga D
    J Transl Med; 2019 Jul; 17(1):229. PubMed ID: 31324258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-29b Regulates the Mitochondria-Dependent Apoptotic Pathway by Targeting Bax in Doxorubicin Cardiotoxicity.
    Jing X; Yang J; Jiang L; Chen J; Wang H
    Cell Physiol Biochem; 2018; 48(2):692-704. PubMed ID: 30025410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor II receptor-α is a novel stress-inducible contributor to cardiac damage underpinning doxorubicin-induced oxidative stress and perturbed mitochondrial autophagy.
    Pandey S; Kuo WW; Shen CY; Yeh YL; Ho TJ; Chen RJ; Chang RL; Pai PY; Viswanadha VP; Huang CY; Huang CY
    Am J Physiol Cell Physiol; 2019 Aug; 317(2):C235-C243. PubMed ID: 31116582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhiza glabra (Licorice) root extract attenuates doxorubicin-induced cardiotoxicity via alleviating oxidative stress and stabilising the cardiac health in H9c2 cardiomyocytes.
    Upadhyay S; Mantha AK; Dhiman M
    J Ethnopharmacol; 2020 Aug; 258():112690. PubMed ID: 32105749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.
    Yokoyama C; Aoyama T; Ido T; Kakino A; Shiraki T; Tanaka T; Nishigaki K; Hasegawa A; Fujita Y; Sawamura T; Minatoguchi S
    PLoS One; 2016; 11(5):e0154994. PubMed ID: 27195769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irigenin treatment alleviates doxorubicin (DOX)-induced cardiotoxicity by suppressing apoptosis, inflammation and oxidative stress via the increase of miR-425.
    Guo L; Zheng X; Wang E; Jia X; Wang G; Wen J
    Biomed Pharmacother; 2020 May; 125():109784. PubMed ID: 32092815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis.
    Tavakoli Dargani Z; Singla DK
    Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H460-H471. PubMed ID: 31172809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heat shock protein 27 attenuated doxorubicin-induced myocardial damage by reducing cardiomyocyte apoptosis, mitochondria damage and protein carbonylation].
    Liu L; Zhang XJ; Qian B; Min XY; Cheng YL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Nov; 36(11):1021-6. PubMed ID: 19102918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats.
    Hang P; Zhao J; Sun L; Li M; Han Y; Du Z; Li Y
    J Cell Mol Med; 2017 Apr; 21(4):685-696. PubMed ID: 28098423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-Induced Myocardial Fibrosis Involves the Neurokinin-1 Receptor and Direct Effects on Cardiac Fibroblasts.
    Levick SP; Soto-Pantoja DR; Bi J; Hundley WG; Widiapradja A; Manteufel EJ; Bradshaw TW; Meléndez GC
    Heart Lung Circ; 2019 Oct; 28(10):1598-1605. PubMed ID: 30205930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isorhapontigenin protects against doxorubicin-induced cardiotoxicity
    Wang P; Wang M; Hu Y; Chen J; Cao Y; Liu C; Wu Z; Shen J; Lu J; Liu P
    Acta Pharm Sin B; 2021 Mar; 11(3):680-693. PubMed ID: 33777675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired NF-κB signalling underlies cyclophilin D-mediated mitochondrial permeability transition pore opening in doxorubicin cardiomyopathy.
    Dhingra R; Guberman M; Rabinovich-Nikitin I; Gerstein J; Margulets V; Gang H; Madden N; Thliveris J; Kirshenbaum LA
    Cardiovasc Res; 2020 May; 116(6):1161-1174. PubMed ID: 31566215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.